Ipamorelin / CJC-1295 No Dac 10mg

The pairing of CJC-1295 (without DAC) and Ipamorelin is commonly examined in experimental research as a dual-peptide system that engages the growth hormone regulatory network through complementary biological mechanisms. Rather than relying on a single signaling route, this blend activates separate receptor pathways that converge at the level of pituitary growth hormone secretion, allowing coordinated evaluation of multi pathway endocrine regulation (1,2).

CJC-1295, a modified fragment of growth hormone releasing hormone (Mod GRF 1–29), selectively interacts with GHRH receptors on somatotroph cells, initiating adenylate cyclase activation and downstream cAMP-dependent protein kinase signaling associated with growth hormone synthesis and release (3,4). Ipamorelin, by contrast, acts as a selective agonist of the ghrelin receptor (GHS-R1a), triggering Gq/11-mediated intracellular calcium signaling that promotes growth hormone secretion through a distinct intracellular cascade (5,6).

When evaluated together, these peptides provide a useful experimental framework for investigating growth hormone pulse dynamics, intracellular signaling integration, and receptor-level interactions within the hypothalamic pituitary axis under controlled laboratory conditions (2,7).

Introduction

Peptide-based regulators of growth hormone (GH) secretion have long been employed as investigative tools to elucidate endocrine signaling pathways, feedback mechanisms, and the physiological basis of pulsatile hormone release (7,8). Among these, combinations of structurally and functionally distinct growth hormone secretagogues are of particular interest in experimental endocrinology, as they enable concurrent examination of parallel receptor systems involved in pituitary regulation (1). The research blend of CJC-1295 (without DAC) and Ipamorelin represents one such model and is frequently utilized to study coordinated modulation of the growth hormone axis under controlled laboratory conditions (9).

CJC-1295 (Mod GRF 1–29) is a synthetic analogue derived from the biologically active region of endogenous growth hormone–releasing hormone. Structural modifications confer enhanced resistance to enzymatic degradation while preserving receptor specificity, enabling reproducible stimulation of pituitary somatotrophs via GHRH receptor engagement (3,4). This interaction primarily activates adenylate cyclase dependent signaling cascades, providing a reliable framework for examining cAMP-mediated regulation of GH synthesis and secretion (10). Ipamorelin, in contrast, belongs to the class of selective ghrelin receptor agonists and induces growth hormone release through an alternative intracellular mechanism involving phospholipase C activation and calcium mobilization (5,6). Its high receptor selectivity makes it particularly useful for isolating ghrelin-mediated signaling with minimal engagement of non-target pituitary pathways (11).

When investigated together, CJC-1295 (no DAC) and Ipamorelin provide a complementary signaling model that reflects the multi-pathway control of GH pulsatility observed in physiological systems (12). This dual-peptide approach has been applied in preclinical and in vitro studies to explore signal integration, temporal hormone release dynamics, and regulatory interactions within the hypothalamic pituitary axis (13). As such, the CJC-1295 and Ipamorelin blend continues to serve as a valuable experimental construct for advancing mechanistic understanding of peptide-driven endocrine regulation rather than for clinical or therapeutic interpretation.